Pneumotox Online
v2.2
  • RSS Feed
  • Contact
  • News
  • Diagnosing DIRD
  • Browse
  • Available on AppStore Available on AppStore

The Drug-Induced Respiratory Disease Website

Philippe Camus, M.D.

Dijon, France

  • Home
  • Browse by »
  • Drugs
  • Patterns

Bevacizumab

3

III.g Bleeding/hemorrhage from/around preexisting lung tumor (Localized AH)

2
Last update : 17/03/2014
 
Search
Advanced search
Identify causative drugs
Diagnosing DIRD
1
Drug and radiation history
2
Drug singularity - Correct identification of the drug
3
Consistent timing of exposure v. onset of symptoms
4
Clinical, imaging, BAL, pathological pattern consistent with the specific drug
5
Careful exlusion of another cause
6
Remission of symptoms with removal of drug
7
Recurrence with rechallenge (rarely advisable)
8
Causality assessment
More detailed checklist
See also under
Pazopanib
2
Sorafenib
2
Sunitinib
2

Publications

Bevacizumab for the treatment of nonsquamous non-small-cell lung cancer in Portugal: a retrospective, multicenter study.
Cancer management and research 2012;4;91-7 2012
Retrospective evaluation of the clinical and radiographic risk factors associated with severe pulmonary hemorrhage in first-line advanced, unresectable non-small-cell lung cancer treated with Carboplatin and Paclitaxel plus bevacizumab.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009 Mar 20;27;1405-12 2009 Mar 20
Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer.
The New England journal of medicine 2006 Dec 14;355;2542-50 2006 Dec 14

Powered by

  • ^
  • Contact
  • Cookies
  • About